97182 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
GLYCOTARGETING THERAPEUTICS
#2ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
#3METHODS FOR THE DIAGNOSIS AND TREATMENT OF T-CELL MALIGNANCIES
#4Library of Antigen-Binding Molecules Including Modified Antibody Variable Region
#5ENHANCED DEPLETION OF TARGETED CELLS WITH CD47 BLOCKADE AND AN IMMUNE COSTIMULATORY AGONIST
#6ALPHA V-INTEGRIN TARGETED SMALL MOLECULE DRUG CONJUGATES
#7METHODS AND COMPOSITION FOR THE SELECTIVE ENHANCEMENT OF ADOPTIVE CELL THERAPY
#8Targeting Extracellular Matrix Proteins to Regulate NK Cell Function in Peripheral Tissues
#9USE OF ALPHA-V-INTEGRIN (CD51) INHIBITORS FOR THE TREATMENT OF CARDIAC FIBROSIS
#10COMPOSITIONS AND METHODS FOR TARGETING AND KILLING ALPHA-V BETA-3-POSITIVE CANCER STEM CELLS (CSCS) AND TREATING DRUG RESISTANT CANCERS
#11Sialylated Glycoproteins
#12ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
#13THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
#14METHODS FOR TREATING DRUG RESISTANT CANCERS
#15Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
#16Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
#17COMPOSITIONS AND METHODS FOR TREATING CANCER
#18GLYCOTARGETING THERAPEUTICS
#19Method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
#20ULTRAMODULAR IGG3-BASED SPACER DOMAIN AND MULTI-FUNCTION SITE FOR IMPLEMENTATION IN CHIMERIC ANTIGEN RECEPTOR DESIGN
#21Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
#22ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED FC REGION
#23ANTI-GPIIB/IIIA ANTIBODIES OR USES THEREOF
#24Methods of Engineering Surface Charge for Bispecific Antibody Production
#25ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
#26COMPOSITIONS AND METHODS FOR TREATING NECROTIZING ENTEROCOLITIS
#27Library of antigen-binding molecules including modified antibody variable region
#28Process for lyophilized pharmaceutical formulations of a therapeutic protein
#29CHIMERIC CLOTTING FACTORS
#30USE OF ALPHA-V-INTEGRIN (CD51) INHIBITORS FOR THE TREATMENT OF CARDIAC FIBROSIS
#31PROCESSABLE SINGLE CHAIN MOLECULES AND POLYPEPTIDES MADE USING SAME
#32MULTISPECIFIC MOLECULES THAT BIND TO MYELOPROLIFERATIVE LEUKEMIA (MPL) PROTEIN AND USES THEREOF
#33ANTI-GPIIB/IIIA ANTIBODIES AND USES THEREOF
#34Antibodies against HPA-1a
#35ENHANCING THE THERAPEUTIC ACTIVITY OF IMMUNE CHECKPOINT INHIBITOR
#36Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#37Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
#38COMPOSITIONS AND METHODS FOR TARGETING AND KILLING ALPHA-V BETA-3-POSITIVE CANCER STEM CELLS (CSCS) AND TREATING DRUG RESISTANT AND METASTATIC CANCERS
#39ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
#40Antigen-binding molecule containing modified antibody variable region
#41Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
#42Glycotargeting therapeutics
#43Abituzumab for the treatment of colorectal cancer
#44COMPOSITIONS AND METHODS FOR TARGETING AND KILLING ALPHA-V BETA-3-POSITIVE CANCER STEM CELLS (CSCS) AND TREATING DRUG RESISTANT CANCERS
#45ANTI-GPIIB/IIIA ANTIBODIES OR USES THEREOF
#46Sialylated Glycoproteins
#47Disintegrin variants and pharmaceutical uses thereof
#48Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
#49Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#50Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
#51Compositions and methods to treat solid tumors
#52ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF PROSTATE CANCER
#53ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS
#54PROCESS FOR LYOPHILIZED PHARMACEUTICAL FORMULATION OF A THERAPEUTIC PROTEIN
#55Methods of engineering surface charge for bispecific antibody production
#56Methods and Compositions For the Treatment of Proteinuric Diseases
#57MILK FAT GLOBULE EPIDERMAL GROWTH FACTOR 8 REGULATES FATTY ACID UPTAKE
#58Sialylated glycoproteins
#59Processable single chain molecules and polypeptides made using same
#60Glycotargeting therapeutics
#61Library of antigen-binding molecules including modified antibody variable region
#62DIAGNOSTIC ASSAYS FOR SUPAR-β3 INTEGRIN DRIVEN KIDNEY DISEASES
#63Antibodies to tumor associated complex N-glycans with terminal GlcNAcβ residues and methods of use thereof
#64COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
#65Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#66Monoclonal Antibodies for Enhancing or Inhibiting Insulin-Like Growth Factor 1 (IGF-1)
#67Anti-GPIIB/IIIA antibodies and uses thereof
#68ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
#69Method of treating solid cancers and/or metastases thereof with pan AV integrin inhibitor, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
#70Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
#71Multivalent and monovalent multispecific complexes and their uses
#72Enhancing the therapeutic activity of immune checkpoint inhibitor
#73Antibodies against HPA-1a
#74Compositions and methods to treat solid tumors
#75SPATIOTEMPORALLY MULTICONTROLLABLE INTELIGENT DRUG-ELUTING STENT
#76Chimeric clotting factors
#77Glycotargeting therapeutics
#78ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
#79SIALYLATED GLYCOPROTEINS
#80INTEGRIN-MODULATING THERAPIES FOR TREATING FIBROTIC DISEASE
#81CXCL12 (CHEMOKINE (C-X-C MOTIF) LIGAND 12) AND IGFBP2 INHIBITORS FOR THE APPLICATION IN THE TREATMENT OF DIABETES MELLITUS ASSOCIATED PANCREATIC CANCER
#82Antibody targeting through a modular recognition domain
#83Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#84Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
#85CHIMERIC FVII-XTEN MOLECULES AND USES THEREOF
#86Anti-GPIIB/IIIA antibodies or uses thereof
#87EGFR-binding modular recognition domains
#88Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
#89Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
#90Multivalent and Monovalent Multispecific Complexes and Their Uses
#91Antigen-binding molecule containing modified Fc region
#92Use of integrin beta subunits in the diagnosis of venous thromboembolism
#93Method for Overcoming Tolerance to Targeted Anti-Cancer Agent
#94Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
#95Single chain antibodies that specifically bind to the activated state of the platelet integrin receptor GP IIb/IIIa
#96Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
#97Phage antibodies to radiation-inducible neoantigens
#98Anti-alpha-V integrin antibody for the treatment of prostate cancer
#99Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
#100Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof
#101Humanized single-chain antibody against beta 3 integrin for the treatment and prevention of metastasis
#102Separation of living untouched neurons
#103Immunoglobulin cleavage fragments and disease indicators and compositions for detecting and binding such
#104Cell display of antibody libraries
#105Processable single chain molecules and polypeptides made using same
#106Antibody targeting through a modular recognition domain
#107Temperature sensitive conjugate compositions
#108Methods and compositions for treating and preventing disease associated with αvβ5 integrin
#109Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
#110Antibody Mimetic Scaffolds
#111Compositions and methods for diagnosis and treatment of tumors
#112Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
#113Compositions and methods for biological remodeling with frozen particle compositions
#114Compositions and methods for biological remodeling with frozen particle compositions
#115Insulin-like growth factor signaling and integrin
#116ANTI- INTEGRIN ANTIBODIES, COMPOSITIONS, METHODS AND USES
#117ERBB2 antibodies comprising modular recognition domains
#118Phage antibodies to radiation-inducible neoantigens
#119VEGF antibodies comprising modular recognition domains
#120Multispecific antibody targeting and multivalency through modular recognition domains
#121INHIBITION OF COMPLEMENT AND CELLULAR ACTIVATION
#122METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING CD2 ANTAGONISTS IN COMBINATION WITH OTHER PROPHYLACTIC OR THERAPEUTIC AGENTS
#123NEUREGULIN/ERBB SIGNALING AND INTEGRIN
#124Antibody Targeting Through a Modular Recognition Domain
#125Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
#126Cytomegalovirus disintegrin-like peptides
#127METHODS OF ADMINISTERING/DOSING CD2 ANTAGONISTS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISORDERS OR INFLAMMATORY DISEASES
#128Targeted Coagulation Factors and Method of Using the Same
#129Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
#130AGENTS THAT DISSOLVE ARTERIAL THROMBI
#131Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
#132Mutant antibody Fc domains and fusion proteins thereof
#133Compositions and methods for diagnosis and treatment of tumors
#134Anti-ADAM-15 antibodies and utilization of the same
#135Methods and compositions for the treatment of proteinuric diseases
#136Integrin αβspecific antibodies and peptides
#137Antithrombotic Neurovascular Device Containing a Glycoprotein IIB/IIIA Receptor Inhibitor for The Treatment of Brain Aneurysms and/or Acute Ischemic Stroke, and Methods Related Thereto
#138Protein Formulations
#139EPH RECEPTOR Fc VARIANTS WITH ENHANCED ANTIBODY DEPENDENT CELL-MEDIATED CYTOTOXICITY ACTIVITY
#140GPIIIa gene
#141Increasing The Production Of Recombinant Antibodies In Mammalian Cells By Site-Directed Mutagenesis
#142Polypeptides that bind membrane proteins
#143Compositions and methods for biological remodeling with frozen particle compositions
#144Compositions and methods for biological remodeling with frozen particle compositions
#145Compositions and methods for biological remodeling with frozen particle compositions
#146Agents, Which Inhibit Apoptosis in Cells that are Involved in Wound Healing
#147Compositions and methods for biological remodeling with frozen particle compositions
#148ANTICOAGULATION AGENT AND USES THEREOF
#149Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
#150Method for enhancing or inhibiting insulin-like growth factor-I
#151Anti-integrin antibodies, compositions, methods and uses
#152Anti-integrin antibodies, compositions, methods and uses
#153Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
#154Prevention or Treatment of Cancer Using Integrin alphavbeta3 Antagonists in Combination with Other Agents
#155Anticoagulation Agent and Uses Thereof
#156Compositions and methods for diagnosis and treatment of tumors
#157METHODS AND COMPOSITIONS FOR INHIBITION OF METASTASIS
#158CYR61 COMPOSITIONS AND METHODS
#159Stabilized High Concentration Anti-Integrin alphavbeta3 Antibody Formulations
#160Methods of Preventing or Treating Inflammatory or Autoimmune Disorders by Administering Integrin ALPHAVBETA3 Antogonists in Combination with other Prophylactic or Therapeutic Agents
#161Monoclonal antibodies against βintegrins
#162Devices, compositions and methods for the protection and repair of cells and tissues
#163αvβ3-specific antibodies
#164Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
#165Phage antibodies to radiation-inducible neoantigens
#166Methods of treating neovascular glaucoma, macular degeneration and capillary proliferation with alphavbeta3-specific antibodies
#167ANTI-ALPHABETA3 HUMANIZED MONOCLONAL ANTIBODIES
#168Protein Formulations
#169ANTI-OSTEOPONTIN ANTIBODY AND USE THEREOF
#170Inflammatory Cytokine Inhibitors
#171Antibody of human origin specifically binding to activated state of platelet integrin receptor GPIIb/IIIa
#172Method for treating autoimmune diseases and compositions therefor
#173Anti-integrin antibodies, compositions, methods and uses
#174ανβ3 integrin-binding polypeptide monobodies and their use
#175Cell display of antibody libraries
#176Anti-αβhumanized monoclonal antibodies
#177Combination therapies for inhibiting integrin-extracellular matrix interactions
#178Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
#179Agents that dissolve arterial thrombi
#180Immunoglobulin
#181Methods for inhibition of angiogenesis
#182Method for treating or preventing steroid-induced glaucoma
#183Compositions and methods for producing enhanced antibodies
#184Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis
#185Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof
#186Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
#187Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
#188Method and compositions for treating diseases targeting CD51
#189Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
#190Recombinant anti-osteopontin antibody and use thereof
#191Method for enhancing or inhibiting insulin-like growth factor-I
#192Cytomegalovirus disintegrin-like peptides
#193Methods and compositions for inhibition of metastasis
#194Anti-angiogenic proteins and fragments and methods of use thereof
#195Monoclonal antibodies with reduced immunogenicity
#196Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
#197Vitro methods for determining in vivo thrombotic events
#198Anti-angiogenic uses of IL-6 antagonists
#199Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
#200Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
#201Methods of treating arthritis and diabetic retinopathy with αβ-specific antibodies